Aptose Biosciences Inc. (NASDAQ:APTO) Q2 2023 Earnings Call Transcript
Operator: Good afternoon. My name is Zeda and I will be your conference operator today.
Aptose Biosciences Inc. (APTO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 146,232 | $678,516 | 0.06% | |
| 2. | Carlson Capital Clint Carlson | 106,666 | $494,930 | 0.04% | |
| 3. | Voss Capital Travis Cocke | 14,634 | $67,902 | 0% | |
| 4. | Millennium Management Israel Englander | 0 | $0 | 0% | |
| 5. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.14 | 17,000 | 17,000 | 2023-09-22 | Filing | ||
| $0.68 | 10,000 | Officer, Director | 363,252 | 2022-09-19 | Filing | |
| $0.68 | 10,000 | Officer | 10,000 | 2022-09-19 | Filing | |
| $0.97 | 10,000 | Officer, Director | 353,252 | 2022-06-06 | Filing | |
| $1.45 | 10,000 | Director | 31,671 | 2021-12-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.62 | 60,000 | Large Shareholder | 8,888,275 | 2021-08-05 | Filing | |
| $3.24 | 9,600 | Director | 15,000 | 2021-06-22 | Filing | |
| $3.35 | 15,400 | Director | 24,600 | 2021-06-21 | Filing | |
| $4.11 | 10,000 | Director | 40,000 | 2020-12-22 | Filing | |
| $4.01 | 10,000 | Director | 50,000 | 2020-12-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 47,082 | $218,461 | 0% | |
| 2. | 35,472 | $164,590 | 0% | |
| 3. | 2,020 | $9,373 | 0% | |
| 4. | 1,526 | $8,000 | 0% | |
| 5. | 1,712 | $7,943 | 0% |
News See All
Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2023 Earnings Call Transcript
Operator: Good afternoon. My name is Antoine Alexander and I will be your conference operator today.
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2022 Earnings Call Transcript
Operator: Hello and thank you for standing by and welcome to Aptose Biosciences reports for the Fourth Quarter and Yearend 2022 Conference Call. At this time, all participants on a listen-only mode.
10 Micro-Cap Stocks to Buy According to Hedge Funds
In this article, we will discuss 10 micro-cap stocks to buy according to hedge funds.
5 Stocks to Buy Under $15 According to Travis Cocke’s Voss Capital
In this article, we discuss the 5 stocks to buy under $15 according to Travis Cocke’s Voss Capital.
Hedge Funds Are Crazy About Aptose Biosciences Inc (APTO)
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities...
10 Best Small-Cap Biotech Stocks Under $10 in 2021
We like healthcare and technology industries because of their above-average long-term growth prospects. Biotechnology is at the intersection of healthcare and technology.
Is APTO A Good Stock To Buy Now According To Hedge Funds?
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious...
Here is What Hedge Funds Think About Aptose Biosciences Inc (APTO)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Is Aptose Biosciences Inc (APTO) A Good Stock To Buy?
In this article you are going to find out whether hedge funds think Aptose Biosciences Inc (NASDAQ:APTO) is a good investment right now.
Billionaire Hedge Funds
